Vinformide (also known as N-formylleurosine), an N-formyl analog of leurosine possesses antineoplastic activity. This drug was studied for the treatment of lymphoma, leukemia and Hodkin’s disease. However, studies were discontinued, because vinformide exerted an acute cardiotoxic side effect.

Salnacedin (also known as G 201) was developed as a topical anti-inflammatory agent; Salnacedin participated in phase II clinical trials in the USA for the treatment of dermatitis, acne, and psoriasis. However, all these studies were discontinued.

Mimbane was developed by Parke-Davis as an analgesic. Information about the current use of the drug is not available.

Treloxinate is a potent hypolipidemic agent. Treloxinate and its acid are structurally related to clofibrate. The activities of treloxinate and its acid form have been found to be identical. In rats treloxinate is 8 times as potent as clofibrate in reducing plasma cholesterol levels and 30 times as potent in lowering plasma triglyceride concentration.

Chloracyzine is phenothiazine derivative with vasodilatory activity. Chloracyzine produced a decrease in myocardial oxygen consumption accompanied by a reduction in coronary blood flow preceded by transient coronary dilatation. Chloracyzine produced an insignificant increase in arterial pressure; heart rate increased slightly in the open-chest experiments but not in the isolated heart. It is suggested that reduced oxygen uptake after chloracyzine is realized through improved efficiency in the use of oxygen.

There is no information about biological and/or pharmacological application of phenbutazone sodium glycerate.

Dimpylate (diazinon) is a nonsystemic organophosphate insecticide, an inhibitor of the enzyme acetylcholinesterase (AChE), which hydrolyzes the neurotransmitter acetylcholine (ACh) in cholinergic synapses and neuromuscular junctions. This results in abnormal accumulation of ACh in the nervous system. Dimpylate was first registered for use in the USA in 1956. It was developed as an insecticide, acaricide, and nematicide for use on a variety of pests for control of soil insects and pests of fruit, vegetables, and forage and field crops. It had been used extensively in home and garden applications, in formulations designed to prevent such pests as crickets or cockroaches from infesting homes or offices, and in pet collars. Due to the emerging health and ecological risks posed by diazinon, manufacturers agreed to phase out and cancel all residential products. Manufacturing of indoor use products containing dimpylatewas discontinued in 2001; manufacture of non-agricultural outdoor use products containing dimpylate was discontinued in 2003.

Thiamiprine is a cytotoxic purine derivative patented by Wellcome Foundation Ltd. as an immunosuppressive and antineoplastic agent. In preclinical models, Thiamiprine is active against a variety of transplantable rodent tumors and in the rat adjuvant arthritis model.

Khelloside is a component of Ammi visnaga L. fruits extract, a medicine which is used in Egypt as remedy for the treatment of kidney stones. Khelloside itself exhibits a wide variety of biological activities including anti-anginal, antiatherosclerotic, lipid altering, antipyretic and spasmolytic. It was clinically tested for asthma, angina pectoris and skin disease, however its develoment seems to be discontinued.